Apotex Q1 FY27 adjusted EBITDA drops 54% to CAD 259.3 million; revenue falls 25.8% to CAD 848 million
Reuters2026/08/12 10:01- Apotex posted Q1 FY2027 revenue of CAD 848 million, down 26% year over year; IFRS net loss was CAD 38.3 million.
- IFRS operating income fell 85.29% to CAD 71.7 million, while adjusted EBITDA (non-IFRS) dropped 54.3% to CAD 259.3 million.
- Adjusted EBITDA margin (non-IFRS) narrowed 19 percentage points to 30.6%.
- Canada revenue climbed 11.5% to CAD 412.7 million, while U.S. revenue sank 48.5% to CAD 362.9 million.
- Outlook held for upper mid-single digit revenue growth with ~30% adjusted EBITDA margin; CAD 0.06 dividend declared, payable Sept. 30.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y
As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
Crypto prices
More
